JAK3 mutations ID'd in about one-third of T-cell lymphomas

Share this article:
<i>JAK3</i> Mutations ID'd in About One-Third of T-Cell Lymphomas
<i>JAK3</i> Mutations ID'd in About One-Third of T-Cell Lymphomas

(HealthDay News) -- Approximately one-third of patients with natural killer/T-cell lymphoma (NKTCL) harbor somatic-activating Janus kinase 3 (JAK3) mutations, according to a study published online June 15 in Cancer Discovery.

Ghee Chong Koo, Ph.D., from the National Cancer Centre Singapore, and colleagues conducted whole-exome sequencing in four patients with NKTCLs. In 61 additional cases, the prevalence of JAK3 mutations was investigated using Sanger sequencing and high-resolution melt analysis.

In two of the four patients who underwent whole-exome sequencing, the researchers identified JAK3 somatic-activating mutations (A572V and A573V). Further analysis demonstrated that 35.4 percent of cases harbored JAK3 mutations. The JAK3 mutations were suggested to be involved in cytokine-independent JAK/STAT constitutive activation, leading to enhanced growth. Inhibition with the novel pan-JAK inhibitor CP-690550 resulted in dose-dependent reduction of phosphorylated STAT5, reduced cell viability, and increased apoptosis in both JAK3-mutant and wild-type NKTCL cell lines.

"In summary, our studies identified, for the first time, frequent JAK3 mutations in NKTCLs," the authors write. "They also indicated that targeting the JAK/STAT pathway in this disease is a potentially effective therapeutic approach that warrants further investigation."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Poor parent-provider communication seen in advanced pediatric cancer

Poor parent-provider communication seen in advanced pediatric cancer

For pediatric patients with advanced cancer, parent-provider concordance is poor regarding prognosis and goals of care, according to a study.

Testicular cancer on the rise for young U.S. Hispanics

Testicular cancer on the rise for young U.S. ...

An increase in incidence of testicular germ cell tumors in Hispanic adolescents and young adults in the United States has been observed.

Rates of observation as prostate cancer management vary

Rates of observation as prostate cancer management vary

Rates of observation as management for low-risk prostate cancer vary widely, and primary ADT is not tied to better survival for men with localized prostate cancer.